Fas Ligand Protein (Fas Ligand)

A transmembrane protein belonging to the tumor necrosis factor superfamily that was originally discovered on cells of the lymphoid-myeloid lineage, including activated T-LYMPHOCYTES and NATURAL KILLER CELLS. It plays an important role in immune homeostasis and cell-mediated toxicity by binding to the FAS RECEPTOR and triggering APOPTOSIS.

Also Known As:

Networked: 2275 relevant articles (30 outcomes, 229 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Weller, M: 16 articles (04/2008 - 01/2000)
2.	Yagita, Hideo: 14 articles (06/2014 - 02/2002)
3.	Krammer, P H: 9 articles (09/2015 - 10/2000)
4.	Kuo, Po-Lin: 9 articles (05/2014 - 09/2004)
5.	Fukunaga, Kohji: 9 articles (01/2012 - 08/2002)
6.	Zou, Ping: 9 articles (10/2006 - 01/2002)
7.	Krammer, Peter H: 8 articles (11/2015 - 02/2003)
8.	Peter, Marcus E: 8 articles (04/2014 - 08/2004)
9.	Legembre, Patrick: 8 articles (11/2013 - 08/2004)
10.	Hsu, Ya-Ling: 8 articles (10/2011 - 09/2004)

Related Diseases

1.	Neoplasms (Cancer) 12/01/2012 - "The composition of cancerous exosomes has been proven to play pivotal roles in the maintenance of the microenvironment that is beneficial for the progression of cancer, such as Fas-ligand-triggered lymphocyte apoptosis. " 12/01/2012 - "Fas ligand (FasL) gene therapy for cancer has shown promise in rodents; however, its efficacy in higher mammals remains unknown. " 06/01/2014 - "Several studies have assessed the association of CD95L polymorphism with cervical cancer risk, but the data lack the power to provide compelling evidence. " 05/01/2014 - "Genetic polymorphisms in the Fas/Fas ligand (FasL) gene were proposed to be associated with susceptibility to cervical cancer, but previous studies reported controversial findings. " 01/01/2013 - "Published studies investigating the association between genetic polymorphism -884C/T (rs763110) of the FAS ligand (FASL) promoter and cancer risk reported inconclusive results. "
2.	Neoplasm Metastasis (Metastasis) 12/01/2011 - "Low preoperatives CD95L levels may help identify a subgroup of patients with synchronous liver metastases that are likely to benefit from liver surgery." 12/01/2011 - "Preoperatives CD95L is a potential prognostic factor for RFS and OS of patients undergoing surgery for synchronous colorectal liver metastases. " 12/01/2011 - "To assess whether circulating soluble CD95 ligand (sCD95L) levels are associated with recurrence-free survival (RFS) in patients with synchronous colorectal liver metastases. " 12/01/2010 - "Micro-metastases in the hypoxic transition zone following RFA displayed a highly invasive phenotype and increased expression of CD95 and CD95L. " 01/01/2007 - "Moreover, negative staining for Fas or the lack of Fas-ligand expression proved to be significant predictors for the survival free from bone metastases under univariate analysis. "
3.	Heart Failure 05/15/1999 - "This study also indicates that the failing heart may contribute to the increased concentration of soluble Fas ligand in patients with congestive heart failure." 01/01/2012 - "The Fas/Fas Ligand system is a major apoptosis signaling pathway that is up-regulated in patients with chronic heart failure (CHF). " 06/01/2006 - "We postulate that the Fas ligand (FasL) derived from the infiltrating mononuclear cells causes death of cardiac cells resulting in the development of heart failure. " 09/17/2004 - "Blockade of this apoptosis by interfering with the Fas/Fas ligand interaction may become one of the therapeutic strategies against chronic heart failure after large MI." 05/15/1999 - "The circulating levels of soluble Fas ligand was increased in patients with advanced congestive heart failure. "
4.	Melanoma (Melanoma, Malignant) 08/01/2010 - "Overexpression of the death ligand CD95L/FasL has been shown in previous studies as highly effective for apoptosis induction in melanoma cells. " 07/01/2010 - "FAS, FAS ligand, tumor infiltrating lymphocytes, and macrophages in malignant melanoma: an immunohistochemical study." 08/01/1998 - "The present study indicates the significant correlation between tumorigenicity and expression of CD95L, and thereby raises the possibility that CD95L may be a useful diagnostic marker for malignant melanomas." 08/01/1998 - "In this study, we employed immunohistochemistry using an antibody directed against CD95L to investigate at which stage the melanoma CD95L expression is turned on. " 03/01/2007 - "To this end we used a Fas ligand (FasL)-expressing melanoma cell line in a mouse model. "
5.	Infection 08/01/2001 - "In contrast, mice with defects in the Fas/Fas ligand (FasL)-mediated cytotoxicity pathway exhibit delayed clearance of adenovirus from the liver without apparent delay in the clearance of viral infections from extrahepatic organs. " 04/15/2010 - "Previous studies have shown that the reduction in CD8 T cell immunity observed during high-dose influenza A virus (IAV) infection is mediated via lymph node (LN) dendritic cells (DCs) that express Fas ligand (FasL) and drive FasL-Fas (DC-T)-induced apoptosis. " 11/01/2009 - "In this study, we examined the roles of Fas-Fas ligand (FasL) signaling in lethal infection with HSV-2 by using mice with mutated Fas (lpr) or FasL (gld) in C57BL/6 background. " 11/01/2007 - "In this study, we evaluated the contribution of Fas-Fas ligand (FasL) interactions to CD8+ T-cell-mediated control of WNV infection. " 08/01/2006 - "The aim of this study was to analyze the expression levels of TGFbeta1, soluble form of CD95, CD95 ligand (sCD95 and sCD95L, respectively) in plasma and CD95 expression on CD3(+) cells, CD38 expression on CD8(+) cells in liver transplanted recipients with active HCMV infection. "

Related Drugs and Biologics

1.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
2.	Fas Ligand Protein (Fas Ligand)
3.	simendan (Levosimendan)
4.	Cytokines
5.	Interleukin-10 (Interleukin 10)
6.	Interleukins
7.	Interleukin-6 (Interleukin 6)
8.	Interferon-gamma (Interferon, gamma)
9.	Messenger RNA (mRNA)
10.	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Immunotherapy
3.	Ligation
4.	Transplantation (Transplant Recipients)
5.	Intraperitoneal Injections